ANGPTL3 and metabolic syndrome: Observational studies have shown that increased concentrations of these proteins may reflect cardiovascular risk and suggest that treatment of patients with dyslipidemia with ANGPTL3 inhibitors may decrease the CVD risk [6,7,8].